Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

Grace D. Cullen, Heidi D. Finnes, Svetomir N. Markovic, Gerald W. Volcheck

Research output: Contribution to journalArticlepeer-review


Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.

Original languageEnglish (US)
Pages (from-to)402-404
Number of pages3
JournalMelanoma research
Issue number4
StatePublished - Aug 1 2021


  • B-raf (BRAF)
  • dabrafenib
  • hypersensitivity reaction

ASJC Scopus subject areas

  • Dermatology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Successful encorafenib desensitization in a patient with recurrent metastatic melanoma'. Together they form a unique fingerprint.

Cite this